Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Highlights Breast Cancer Awareness Month by Addressing Gaps in Screening and Advancing the IzoView Breast CT Solution

• Izotropic highlights recurrent challenges in current breast imaging technologies and the need for high-resolution, true 3D imaging
• The IzoView breast CT scan technology is created for accurate, compression-free imaging for women who have dense breast tissue
• Increased screening demands and regulatory momentum underscore the opportunities for dedicated breast CT solutions
• IZOZF’s innovative approaches highlight the company’s mission to improve diagnosis, detection, and care for people globally

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device firm leading imaging-based solutions for better diagnosis, screening, and treatment of breast cancer patients, is bringing the challenges of current screening systems and the unique potential of the IzoView Breast CT Imaging solutions as part of efforts to mark Breast Cancer Awareness Month (ibn.fm/Hml57).

Breast cancer accounts for a third of cancer diagnoses among American women, making the need for better imaging solutions critical. Current solutions like tomosynthesis, mammography, and ultrasound are limited by tissue overlap, compression, and a high rate of false positives. These issues are quite common among women with dense breast tissue, a situation common among over 50% of women within the screening-age group.

The firm’s IzoView Breast CT was created to solve these issues. IzoView can capture about 500 high-resolution images in less than 10 seconds with the patients lying face down and without breast compression. Studies at UC Davis, where the initial breast CT technology was created and licensed exclusively to Izotropic, have revealed malignant masses to be more obvious on optimized breast CT than on DBT or mammography, with a spatial resolution reaching 100 times more than magnetic resonance imaging.

Izotropic’s strategy attempts to close the gap between MRI and digital breast tomosynthesis, giving imaging centers and hospitals a better, mid-range option that boosts the accuracy of detection, devoid of the attendant complexity and cost of MRI technology. IzoView’s projected price of USD $500,000 means it will be adopted across the healthcare ecosystem.

With regulatory organizations like the U.S. Preventive Services Task Force and the FDA scaling up efforts in ensuring better imaging for women with dense tissues, Izotropic’s solution perfectly syncs with policy directions and emerging clinical needs. Recent mandates in America necessitate breast density notifications after mammography, highlighting the urgency and market opportunity for better imaging options.

With a core focus on the breast imaging industry, Izotropic is changing the way diagnosis and the comfort of patients are provided. These updates highlight the firm’s vision to empower clinicians with next-gen imaging tools that help improve patient outcomes and diagnostic confidence and save human lives.

For more information, visit the company’s website at www.IzoCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at ibn.fm/IZOZF

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN